Neuronal inhibition and seizure suppression by acetoacetate and its analog, 2-phenylbutyrate

Epilepsia

Volumn 58, Issue 5, 2017, Pages 845-857

  Kadowaki, Atsushi ^a   Sada, Nagisa ^a   Juge, Narinobu ^b,c   Wakasa, Ayaka ^a   Moriyama, Yoshinori ^a,b   Inoue, Tsuyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antiseizure effect; Hippocampus; Ketogenic diet; Ketone body analog; Voltage dependent Ca2+ channel

Indexed keywords

ACETOACETIC ACID; ANTICONVULSIVE AGENT; BUTAMIRATE; KAINIC ACID; KETONE BODY; VESICULAR GLUTAMATE TRANSPORTER; 2-PHENYLBUTYRIC ACID; ACETOACETIC ACID DERIVATIVE; ARYLBUTYRIC ACID DERIVATIVE; CALCIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL SLICE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NERVE CELL INHIBITION; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SEIZURE; WHOLE CELL PATCH CLAMP; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; INJECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; KETOGENIC DIET; ORGAN CULTURE TECHNIQUE;

ACETOACETATES; ANIMALS; CALCIUM CHANNELS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; FEMALE; HIPPOCAMPUS; IN VITRO TECHNIQUES; INJECTIONS; KAINIC ACID; KETOGENIC DIET; MALE; MICE; MICE, INBRED ICR; NEURAL INHIBITION; ORGAN CULTURE TECHNIQUES; PHENYLBUTYRATES; PYRAMIDAL CELLS;

EID: 85015178807     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13718     Document Type: Article

References (40)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–319.
2. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008;7:500–506.
3. Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971;21:1097–1103.
4. Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 2009;50:1109–1117.
5. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18–61.
6. Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006;60:223–235.
7. Lutas A, Yellen G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 2013;36:32–40.
8. ATP channels. J Neurosci 2007;27:3618–3625.
9. ATP channel opening in response to action potential firing in mouse dentate granule neurons. J Neurosci 2011;31:8689–8696.
10. Juge N, Gray JA, Omote H, et al. Metabolic control of vesicular glutamate transport and release. Neuron 2010;68:99–112.
11. Levin BE, Dunn-Meynell AA, Routh VH. Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Am J Physiol 1999;276:R1223–R1231.
12. 1 receptors. J Clin Invest 2011;121:2679–2683.
13. ATP channels. J Neurosci 2010;30:3886–3895.
14. Garriga-Canut M, Schoenike B, Qazi R, et al. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 2006;9:1382–1387.
15. ATP channel activity confers resistance to epileptic seizures. Neuron 2012;74:719–730.
16. Rouach N, Koulakoff A, Abudara V, et al. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 2008;322:1551–1555.
17. Sada N, Lee S, Katsu T, et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 2015;347:1362–1367.
18. Lester RA, Jahr CE. Quisqualate receptor-mediated depression of calcium currents in hippocampal neurons. Neuron 1990;4:741–749.
19. 2+ channels in central neurons. Neuron 1993;10:889–898.
20. Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001;21:98–108.
21. 2+ channels in neurons by increasing protein tyrosine phosphorylation. J Biol Chem 2002;277:24368–24375.
22. Blair LA, Marshall J. IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron 1997;19:421–429.
23. 1-42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 2008;28:788–797.
24. Won YJ, Lu VB, Puhl HL 3rd, et al. β-Hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. J Neurosci 2013;33:19314–19325.
25. Riban V, Bouilleret V, Pham-Lê BT, et al. Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience 2002;112:101–111.
26. Bough KJ, Valiyil R, Han FT, et al. Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet. Epilepsy Res 1999;35:21–28.
27. Karst H, Wadman WJ, Joëls M. Corticosteroid receptor-dependent modulation of calcium currents in rat hippocampal CA1 neurons. Brain Res 1994;649:234–242.
28. Faas GC, Vreugdenhil M, Wadman WJ. Calcium currents in pyramidal CA1 neurons in vitro after kindling epileptogenesis in the hippocampus of the rat. Neuroscience 1996;75:57–67.
29. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5–8.
30. Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl. 1):S52–S60.
31. Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol 2002;64:355–405.
32. 1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 2003;44:877–885.
33. Rho JM, Anderson GD, Donevan SD, et al. Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)-β-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia 2002;43:358–361.
34. Kimura I, Inoue D, Maeda T, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci USA 2011;108:8030–8035.
35. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312–11319.
36. 50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004;5:866–872.
37. Peña F, Tapia R. Relationships among seizures, extracellular amino acid changes, and neurodegeneration induced by 4-aminopyridine in rat hippocampus: a microdialysis and electroencephalographic study. J Neurochem 1999;72:2006–2014.
38. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9:68–82.
39. 2+ influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002;449:221–228.
40. v2.1 calcium channels. J Pharmacol Exp Ther 2011;336:973–982.